Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis.

Tenca A, Mustonen H, Lind K, Lantto E, Kolho KL, Boyd S, Arola J, Jokelainen K, Färkkilä M.

Liver Int. 2018 Dec;38(12):2329-2339. doi: 10.1111/liv.13899. Epub 2018 Jul 18.

PMID:
29901259
2.

Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis.

Boyd S, Vannas M, Jokelainen K, Isoniemi H, Mäkisalo H, Färkkilä MA, Arola J.

World J Gastroenterol. 2017 Sep 7;23(33):6147-6154. doi: 10.3748/wjg.v23.i33.6147.

3.

Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia.

Pereira P, Aho V, Arola J, Boyd S, Jokelainen K, Paulin L, Auvinen P, Färkkilä M.

PLoS One. 2017 Aug 10;12(8):e0182924. doi: 10.1371/journal.pone.0182924. eCollection 2017.

4.

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group.

Gastroenterology. 2017 Jun;152(8):1975-1984.e8. doi: 10.1053/j.gastro.2017.02.038. Epub 2017 Mar 6.

5.

Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma.

Boyd S, Mustonen H, Tenca A, Jokelainen K, Arola J, Färkkilä MA.

Scand J Gastroenterol. 2017 Feb;52(2):242-249. doi: 10.1080/00365521.2016.1250281. Epub 2016 Nov 3.

PMID:
27806633
6.

Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia.

Boyd S, Tenca A, Jokelainen K, Mustonen H, Krogerus L, Arola J, Färkkilä MA.

Endoscopy. 2016 May;48(5):432-9. doi: 10.1055/s-0041-110792. Epub 2016 Jan 25.

PMID:
26808393
7.

Elevated liver enzymes - what next?

Jokelainen K.

Duodecim. 2016;132(18):1688-92. Review.

PMID:
29188945
8.

[Chronic liver disease and thrombosis risk].

Aberg F, Lassila R, Ilmakunnas M, Jokelainen K, Numminen K, Mäkisalo H.

Duodecim. 2015;131(4):321-30. Review. Finnish.

PMID:
26237922
9.

[Acute hepatitis in a middle-aged woman].

Nordin A, Arola J, Jokelainen K.

Duodecim. 2014;130(13):1329-33. Finnish.

PMID:
25095480
10.

Risk factors for complications of ERCP in primary sclerosing cholangitis.

Ismail S, Kylänpää L, Mustonen H, Halttunen J, Lindström O, Jokelainen K, Udd M, Färkkilä M.

Endoscopy. 2012 Dec;44(12):1133-8. doi: 10.1055/s-0032-1325677. Epub 2012 Oct 29.

PMID:
23108808
11.

[Alpha-1 antitrypsin deficiency].

Kauppi P, Jokelainen K.

Duodecim. 2011;127(18):1911-8. Review. Finnish.

PMID:
22034728
12.
13.

Lactulose reduces intracolonic acetaldehyde concentration and ethanol elimination rate in rats.

Zidi SH, Linderborg K, Väkeväinen S, Salaspuro M, Jokelainen K.

Alcohol Clin Exp Res. 2003 Sep;27(9):1459-62.

PMID:
14506407
14.

Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes.

Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ.

Am J Physiol Gastrointest Liver Physiol. 2003 Feb;284(2):G321-7. Epub 2002 Aug 28.

15.

Arginine reverses ethanol-induced inflammatory and fibrotic changes in liver despite continued ethanol administration.

Nanji AA, Jokelainen K, Lau GK, Rahemtulla A, Tipoe GL, Polavarapu R, Lalani EN.

J Pharmacol Exp Ther. 2001 Dec;299(3):832-9.

PMID:
11714866
16.

Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines.

Nanji AA, Jokelainen K, Fotouhinia M, Rahemtulla A, Thomas P, Tipoe GL, Su GL, Dannenberg AJ.

Am J Physiol Gastrointest Liver Physiol. 2001 Dec;281(6):G1348-56.

18.

Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration.

Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ.

J Pharmacol Exp Ther. 2001 Nov;299(2):638-44.

PMID:
11602676
19.

Covalent adducts of proteins with acetaldehyde in the liver as a result of acetaldehyde administration in drinking water.

Jokelainen K, Parkkila S, Salaspuro M, Niemelä O.

J Hepatol. 2000 Dec;33(6):926-32.

PMID:
11131454
20.

Acetaldehyde production and metabolism by human indigenous and probiotic Lactobacillus and Bifidobacterium strains.

Nosova T, Jousimies-Somer H, Jokelainen K, Heine R, Salaspuro M.

Alcohol Alcohol. 2000 Nov-Dec;35(6):561-8.

PMID:
11093962
21.

Activation of nuclear factor kappa B and cytokine imbalance in experimental alcoholic liver disease in the rat.

Nanji AA, Jokelainen K, Rahemtulla A, Miao L, Fogt F, Matsumoto H, Tahan SR, Su GL.

Hepatology. 1999 Oct;30(4):934-43.

PMID:
10498645
22.

Acetaldehyde prevents nuclear factor-kappa B activation and hepatic inflammation in ethanol-fed rats.

Lindros KO, Jokelainen K, Nanji AA.

Lab Invest. 1999 Jul;79(7):799-806.

PMID:
10418820
23.

Ciprofloxacin administration decreases enhanced ethanol elimination in ethanol-fed rats.

Nosova T, Jokelainen K, Kaihovaara P, Väkeväinen S, Rautio M, Jousimies-Somer H, Salaspuro M.

Alcohol Alcohol. 1999 Jan-Feb;34(1):48-54.

PMID:
10075401
24.

Acetaldehyde inhibits NF-kappaB activation through IkappaBalpha preservation in rat Kupffer cells.

Jokelainen K, Thomas P, Lindros K, Nanji AA.

Biochem Biophys Res Commun. 1998 Dec 30;253(3):834-6.

PMID:
9918814
25.

High blood endotoxin does not affect ethanol elimination in rats.

Nosova T, Jokelainen K, Järveläinen HA, Lindros KO, Salaspuro M.

Alcohol Alcohol. 1998 Sep-Oct;33(5):443-6.

PMID:
9811194
26.

Inhibition of intracolonic acetaldehyde production and alcoholic fermentation in rats by ciprofloxacin.

Visapää JP, Jokelainen K, Nosova T, Salaspuro M.

Alcohol Clin Exp Res. 1998 Aug;22(5):1161-4.

PMID:
9726290
27.

Characteristics of aldehyde dehydrogenases of certain aerobic bacteria representing human colonic flora.

Nosova T, Jokelainen K, Kaihovaara P, Heine R, Jousimies-Somer H, Salaspuro M.

Alcohol Alcohol. 1998 May-Jun;33(3):273-80.

PMID:
9632053
28.

Changes in agonist-antagonist EMG, muscle CSA, and force during strength training in middle-aged and older people.

Häkkinen K, Kallinen M, Izquierdo M, Jokelainen K, Lassila H, Mälkiä E, Kraemer WJ, Newton RU, Alen M.

J Appl Physiol (1985). 1998 Apr;84(4):1341-9.

29.

Effects of acetaldehyde on cell regeneration and differentiation of the upper gastrointestinal tract mucosa.

Homann N, Kärkkäinen P, Koivisto T, Nosova T, Jokelainen K, Salaspuro M.

J Natl Cancer Inst. 1997 Nov 19;89(22):1692-7.

PMID:
9390538
30.

High acetaldehyde levels in saliva after ethanol consumption: methodological aspects and pathogenetic implications.

Homann N, Jousimies-Somer H, Jokelainen K, Heine R, Salaspuro M.

Carcinogenesis. 1997 Sep;18(9):1739-43.

PMID:
9328169
31.

Tropisetron and hangover.

Muhonen T, Jokelainen K, Hook-Nikanne J, Methuen T, Salaspuro M.

Addict Biol. 1997 Oct;2(4):461-2. doi: 10.1080/13556219772525. No abstract available.

PMID:
26735952
32.

Characteristics of alcohol dehydrogenases of certain aerobic bacteria representing human colonic flora.

Nosova T, Jousimies-Somer H, Kaihovaara P, Jokelainen K, Heine R, Salaspuro M.

Alcohol Clin Exp Res. 1997 May;21(3):489-94.

PMID:
9161610
33.

Inhibition of bacteriocolonic pathway for ethanol oxidation by ciprofloxacin in rats.

Jokelainen K, Nosova T, Koivisto T, Väkeväinen S, Jousimies-Somer H, Heine R, Salaspuro M.

Life Sci. 1997;61(18):1755-62.

PMID:
9365222
34.

Aldehyde dehydrogenase activity and acetate production by aerobic bacteria representing the normal flora of human large intestine.

Nosova T, Jokelainen K, Kaihovaara P, Jousimies-Somer H, Siitonen A, Heine R, Salaspuro M.

Alcohol Alcohol. 1996 Nov;31(6):555-64.

PMID:
9010546
35.

Increased acetaldehyde production by mouthwashings from patients with oral cavity, laryngeal, or pharyngeal cancer.

Jokelainen K, Heikkonen E, Roine R, Lehtonen H, Salaspuro M.

Alcohol Clin Exp Res. 1996 Oct;20(7):1206-10.

PMID:
8904972
36.

In vitro alcohol dehydrogenase-mediated acetaldehyde production by aerobic bacteria representing the normal colonic flora in man.

Jokelainen K, Siitonen A, Jousimies-Somer H, Nosova T, Heine R, Salaspuro M.

Alcohol Clin Exp Res. 1996 Sep;20(6):967-72.

PMID:
8892513
37.

High intracolonic acetaldehyde values produced by a bacteriocolonic pathway for ethanol oxidation in piglets.

Jokelainen K, Matysiak-Budnik T, Mäkisalo H, Höckerstedt K, Salaspuro M.

Gut. 1996 Jul;39(1):100-4.

38.

The effects of anabolic androgenic steroids on serum ubiquinone and dolichol levels among steroid abusers.

Karila T, Laaksonen R, Jokelainen K, Himberg JJ, Seppälä T.

Metabolism. 1996 Jul;45(7):844-7.

PMID:
8692019
39.

The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle.

Laaksonen R, Jokelainen K, Laakso J, Sahi T, Harkonen M, Tikkanen MJ, Himberg JJ.

Am J Cardiol. 1996 Apr 15;77(10):851-4.

PMID:
8623738
40.

Hepatotoxicity and absorption of extrahepatic acetaldehyde in rats.

Matysiak-Budnik T, Jokelainen K, Kärkkäinen P, Mäkisalo H, Ohisalo J, Salaspuro M.

J Pathol. 1996 Apr;178(4):469-74.

PMID:
8691329
41.

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.

Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ.

Clin Pharmacol Ther. 1995 Jan;57(1):62-6.

PMID:
7828383
42.

In vitro acetaldehyde formation by human colonic bacteria.

Jokelainen K, Roine RP, Väänänen H, Färkkilä M, Salaspuro M.

Gut. 1994 Sep;35(9):1271-4.

43.

Blood dolichol in lysosomal diseases.

Jokelainen K, Salmela KS, Humaloja K, Roine R, Autio S, Arvio M, Järvelä I, Nykänen I, Palo J, Salaspuro M.

Biochem Cell Biol. 1992 Jun;70(6):481-5.

PMID:
1449714
44.

Serum dolichols in different clinical conditions.

Humaloja K, Roine RP, Salmela K, Halmesmäki E, Jokelainen K, Salaspuro M.

Scand J Clin Lab Invest. 1991 Dec;51(8):705-9.

PMID:
1806986
45.

The effects of moderate drinking and abstinence on serum and urinary beta-hexosaminidase levels.

Kärkkäinen P, Jokelainen K, Roine R, Suokas A, Salaspuro M.

Drug Alcohol Depend. 1990 Feb;25(1):35-8.

PMID:
1969791
46.

An outbreak of infantile diarrhoea associated with a new Escherichia coli serotype 55:B5:32.

GRONROOS JA, JOKELAINEN K.

Ann Paediatr Fenn. 1957;3(1):8-17. No abstract available.

PMID:
13444962
47.

Detection of a new Escherichia coli type, 55:B5:32 associated with infantile diarrhoea.

GRONROOS JA, JOKELAINEN K.

Ann Med Exp Biol Fenn. 1956;34(4):335-40. No abstract available.

PMID:
13444833

Supplemental Content

Loading ...
Support Center